<?xml version="1.0" encoding="UTF-8"?>
<p>Overall, 132/332 (40%) of patients received a transplant (everolimus 39%, control 42%, 
 <italic>P</italic>=0.6), with a minority of these (34/132) being allografts in first remission (20 
 <italic>versus</italic> 14, 
 <italic>P</italic>=0.3). There was no evidence of differences in transplantation rates or types of transplants between the arms (any stem cell transplant 39% 
 <italic>versus</italic> 42%, 
 <italic>P</italic>=0.6; allograft 31% 
 <italic>versus</italic> 34%, 
 <italic>P</italic>=0.6; allograft in first complete remission 9% 
 <italic>versus</italic> 13%, 
 <italic>P</italic>=0.3) (
 <xref rid="t1-1031654" ref-type="table">Table 1</xref>).
</p>
